SEC Form 4 · accession 0001630998-16-000007
Syneos Health, Inc. · SYNH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Gibertini
Officer — President Clinical Development
Period of report
Jan 19, 2016
Accepted (ET)
Jan 21, 2016 · 4:09 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001610950
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common StockF1 | Jan 19, 2016 | A | 11,000 | $0.00 | A | 47,282 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy Class A Common Stock)F2 | $42.88 | Jan 19, 2016 | A | 4,889 | A | — | Jan 19, 2026 | Class A Common Stock | 4,889 | 4,889 | D |
| Performance Restricted Stock UnitsF3 | — | Jan 19, 2016 | A | 16,500 | A | — | — | Class A Common Stock | 16,500 | 16,500 | D |
Explanation of responses
- F1Represents an award of restricted stock units which vests in four equal annual installments of 25% beginning on January 19, 2017, subject to continued employment.
- F2The shares subject to this option vest in four equal annual installments of 25% beginning on January 19, 2017, subject to continued employment.
- F3Each performance restricted stock unit ("PRSU") represents a contingent right to receive one share of Issuer common stock. The PRSUs vest up to one-third upon the achievement of adjusted diluted net income earnings per share ("EPS") goals during each of 2016, 2017 and 2018. EPS will be as reported in the Issuer's Forms 10-K or other reports publicly filed with the Commission. Vesting of target PRSUs may accelerate in certain circumstances, including if the holder's employment is terminated without cause or the holder resigns for good reason at the time of or following a change in control of the Issuer during any performance period.